Literature DB >> 20181895

Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy.

José F Pascual-Pareja1, Lorena Martínez-Prats, Joanna Luczkowiak, Silvana Fiorante, Rafael Rubio, Federico Pulido, Joaquín R Otero, Rafael Delgado.   

Abstract

New commercial techniques for determination of the viral load (VL) in plasma are able to detect as few as 20 copies of HIV-1 RNA/ml. The relevance of this new technical threshold is uncertain. Upon multivariate analysis, factors associated with detection of VLs between 20 and 49 copies/ml by the Cobas TaqMan HIV-1 v2.0 assay in an HIV clinic were the basal VL and time on antiretroviral therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20181895      PMCID： PMC2863897          DOI： 10.1128/JCM.02388-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.

Authors:  Tara L Kieffer; Mariel M Finucane; Richard E Nettles; Thomas C Quinn; Karl W Broman; Stuart C Ray; Deborah Persaud; Robert F Siliciano
Journal:  J Infect Dis       Date:  2004-04-05       Impact factor: 5.226

3.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

4.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

5.  Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Authors:  Jose R Arribas; Rafael Delgado; Alberto Arranz; Rosa Muñoz; Joaquin Portilla; Juan Pasquau; María J Pérez-Elias; Jose A Iribarren; Rafael Rubio; Antonio Ocampo; Matilde Sánchez-Conde; Hernando Knobel; Piedad Arazo; Jesús Sanz; José López-Aldeguer; María L Montes; Federico Pulido
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

6.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

7.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

8.  Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

Authors:  Timothy J Wilkin; John E McKinnon; A Gregory DiRienzo; Katie Mollan; Courtney V Fletcher; David M Margolis; Barbara Bastow; Gary Thal; William Woodward; Catherine Godfrey; Ann Wiegand; Frank Maldarelli; Sarah Palmer; John M Coffin; John W Mellors; Susan Swindells
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

9.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823
  9 in total
  5 in total

1.  Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia.

Authors:  Gudrun Naeth; Robert Ehret; Frank Wiesmann; Patrick Braun; Heribert Knechten; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2012-06-15       Impact factor: 3.402

Review 2.  New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond.

Authors:  Benedict B Hilldorfer; Anthony R Cillo; Guillaume J Besson; Margaret Anne Bedison; John W Mellors
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study.

Authors:  Elie Helou; Sheela Shenoi; Tassos Kyriakides; Marie-Louise Landry; Michael Kozal; Lydia Aoun Barakat
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-11-30

4.  Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.

Authors:  Timothy J Henrich; Brian R Wood; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

5.  A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study.

Authors:  Gisela Leierer; Katharina Grabmeier-Pfistershammer; Andrea Steuer; Mario Sarcletti; Maria Geit; Bernhard Haas; Ninon Taylor; Manfred Kanatschnig; Michaela Rappold; Bruno Ledergerber; Robert Zangerle
Journal:  Open Forum Infect Dis       Date:  2016-06-15       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.